$INNV female arousal. revenues. $0.29 Pr at s

$INNV female arousal. revenues. $0.29
Pr at support.

Revenues Up by 289% to $443,087 for Third Quarter



Shares Outstanding: 23.96M
Float: 9.82M



Website


Recent trades


Headlines

Friday, November 14, 2014
Innovus Pharmaceuticals Provides Third Quarter 2014 Financial Results With Commercial and Corporate UpdateAccesswire (Fri 12:15PM EST)
INNOVUS PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online (Fri 6:07AM EST)

Wednesday, November 5, 2014
Innovus Pharmaceuticals Announces Its Revenue GuidanceAccesswire
INNOVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online

Monday, November 3, 2014
Innovus Pharma CEO, Dr. Bassam Damaj, Featured on Wide World of Stocks TelevisionAccesswire

Tuesday, October 28, 2014
Innovus Announces the Acquisition of Vesele(R), A Safer Proprietary Oral Formualtion to Maximize Nitric Oxide's Beneficial Effects on Sexual Function and Brain HealthAccesswire

Friday, October 24, 2014
Innovus Pharmaceuticals Receives Approval for the Expanded Label Indication for its Zestra(R) Product in Canada for the Temporary Increase of Desire/Arousal in Women with Female Sexual Interest/Arousal DisorderAccesswire

Friday, October 3, 2014
INNOVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under anEDGAR Online (

Thursday, October 2, 2014
Innovus Pharma Announces Podium Presentation at the World Meeting of Sexual Medicine, Discussing the Clinical Efficacy of Zestra(R) in Cancer PatientsGlobeNewswire

Tuesday, September 30, 2014
INNOVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online

Monday, September 29, 2014
SeeThruEquity Initiates Research Coverage on Innovus Pharmaceuticals, Inc. with a Target Price of $1.34Accesswire

Wednesday, September 24, 2014
Innovus Pharma Signs License Agreement With Sothema Laboratories for Zestra(R) and Zestra Glide(R) in the Middle East (Excluding Lebanon and Israel), North Africa and West AfricaGlobeNewswire
INNOVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online

Monday, September 22, 2014
Innovus Pharma Signs License Agreement With Orimed Pharma for Zestra(R), EjectDelay(TM), Sensum+(TM) and Zestra Glide(R) in CanadaGlobeNewswire
INNOVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive AgreementEDGAR Online

Thursday, September 18, 2014
INNOVUS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of EqEDGAR Online
Innovus Pharma Signs Exclusive Marketing Sales and Distribution Agreement With Tramorgan Limited to Market and Distribute Sensum+(TM) in the United KingdomGlobeNewswire

Monday, September 8, 2014
SeeThruEquity Fall Microcap Investor Conference To Be Held Sept 11, 2014Accesswire
Innovus Pharma Expands US Distribution by Signing a Non-Exclusive Sampling and Distribution Agreement With Bulu Box(R) for Zestra(R) in the USGlobeNewswire

Thursday, September 4, 2014
Innovus Pharma to Present at the 2014 Aegis Healthcare Conference in Las Vegas, NV and the See Thru Equity Fall Microcap Investor Conference in New YorkGlobeNewswire

Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP